 |
|
Marked Reduction of Tardive Dyskinesia With Olanzapine
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Tardive dyskinesia (TD) is a syndrome of involuntary hyperkinetic abnormal movements that can occur in predisposed individuals during or shortly after the cessation of long-term antipsychotic drug therapy.1 The focus of clinical work with long-term antipsychotic therapy has been to optimize the benefit-to-risk ratio of adverse events, especially TD. The risk of developing TD is believed to increase with total cumulative drug exposure. This risk, on average, is about 5% per treatment year for the first 5 to 7 years,2 decreasing slightly thereafter but reaching a staggering 68% by 20 years.3 The introduction of atypical antipsychotic medications in this decade has demonstrated therapeutic effects for patients with preexisting TD.4-6 Olanzapine, a new atypical antipsychotic, has recently become available in the United States. It is characterized as a selective monoaminergic antagonist with high-affinity binding to serotonin, dopamine, muscarinic, histamine, and adrenergic receptors.7 The actual risk of TD with olanzapine was examined . . . [Full Text of this Article]Report of Cases
Comment
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Olanzepine-induced tardive dyskinesia
Bella and Piccoli
Br. J. Psychiatry 2003;182
:81-82.
FULL TEXT
Olanzapine-Induced Tardive Dystonia
DUNAYEVICH and STRAKOWSKI
Am. J. Psychiatry 1999;156:1662-1662.
FULL TEXT
Tardive Dyskinesia Associated with Olanzapine
Herran and Vazquez-Barquero
ANN INTERN MED 1999;131:72-72.
FULL TEXT
|
